{"id":10201,"date":"2026-07-15T08:03:03","date_gmt":"2026-07-15T06:03:03","guid":{"rendered":"https:\/\/cleanpeptides.eu\/bpc-157-doseringsguide\/"},"modified":"2026-07-15T08:03:03","modified_gmt":"2026-07-15T06:03:03","slug":"bpc-157-doseringsguide","status":"publish","type":"page","link":"https:\/\/cleanpeptides.eu\/da\/bpc-157-doseringsguide\/","title":{"rendered":"BPC-157 doseringsguide: rekonstituering, dosering og kure"},"content":{"rendered":"<p><em>KUN TIL FORSKNINGSFORM\u00c5L \u2014 IKKE TIL HUMAN BRUG.<\/em> Clean Peptides giver ikke r\u00e5dgivning om dosering eller anvendelse. Denne side samler produktinformation fra Clean Peptides sammen med uafh\u00e6ngigt undervisningsmateriale fra PeptideWiki, kun som forskningsreference. Det er ikke medicinsk r\u00e5dgivning og udg\u00f8r hverken anbefalinger, godkendelser eller instruktioner fra Clean Peptides. Doseringen her stammer fra dyrefors\u00f8g og protokoller fra f\u00e6llesskabet \u2014 ikke fra kliniske fors\u00f8g p\u00e5 mennesker.<\/p>\n<h2 class=\"wp-block-heading\">Hvad er BPC-157?<\/h2>\n<p><strong>BPC-157<\/strong> (Body Protection Compound-157) er et syntetisk pentadecapeptid (15 aminosyrer) afledt af et protein i menneskelig mavesaft. Det er us\u00e6dvanligt stabilt i mavesyre, hvilket muligg\u00f8r b\u00e5de injicerbar og oral administration. Forskningsinteressen er centreret om v\u00e6vsbeskyttende og regenererende egenskaber \u2014 dyrefors\u00f8g viser accelereret heling af sener, ledb\u00e5nd, muskler, nerver, mave-tarm-kanalen og knogler. Mekanismerne omfatter opregulering af v\u00e6kstfaktorer (VEGF, EGF), fremme af angiogenese og modulering af nitrogenoxidsystemet. F\u00e5s som <a href=\"https:\/\/cleanpeptides.eu\/product\/bpc-157-5-mg\/\">BPC-157 5 mg<\/a>&#8211; og <a href=\"https:\/\/cleanpeptides.eu\/product\/bpc-157-10-mg\/\">BPC-157 10 mg<\/a>-h\u00e6tteglas.<\/p>\n<h2 class=\"wp-block-heading\">N\u00f8gleegenskaber<\/h2>\n<ul class=\"wp-block-list\">\n<li>Pentadecapeptid \u2014 15 aminosyrer (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val).<\/li>\n<li>Mavesaftsafledt \u2014 stabilt i mavesyre, us\u00e6dvanligt for peptider.<\/li>\n<li>Flere administrationsveje \u2014 aktivt ved subkutan\/intramuskul\u00e6r injektion og oralt.<\/li>\n<li>V\u00e6vsreparation \u2014 sener, ledb\u00e5nd, muskler, tarmslimhinde, nerver og knogler i dyremodeller.<\/li>\n<li>Angiogenese \u2014 opregulerer VEGF og fremmer dannelsen af nye blodkar ved skadesteder.<\/li>\n<li>Modulering af NO-systemet \u2014 p\u00e5virker blodgennemstr\u00f8mning, bet\u00e6ndelse og signalering af v\u00e6vsreparation.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">S\u00e5dan fastl\u00e6gges doseringen<\/h2>\n<p>Doseringen (i mikrogram) stammer fra dyrefors\u00f8g, allometrisk skalering og omfattende erfaring fra f\u00e6llesskabet. Gnaverfors\u00f8g bruger typisk 10 mcg\/kg \u2013 10 mg\/kg; en almindelig rottedosis p\u00e5 ~10 mcg\/kg skaleret til et menneske p\u00e5 75 kg giver ~300 mcg. Protokollen p\u00e5 250 mcg en til to gange dagligt er de facto-standarden i f\u00e6llesskabet. Evidensstyrke: lav til moderat \u2014 omfattende dyrelitteratur, minimal kontrolleret human forskning.<\/p>\n<h2 class=\"wp-block-heading\">Standarddoseringsintervaller<\/h2>\n<h3 class=\"wp-block-heading\">Subkutant \/ intramuskul\u00e6rt<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Niveau<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Dosis<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Hyppighed<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Bem\u00e6rkninger<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Lav \/ begynder<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">150\u2013200 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">En gang dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Mindre skader, generel restitution<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Standard<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">250 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">En eller to gange dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Mest almindeligt; skader p\u00e5 sener, ledb\u00e5nd, muskler<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Aggressiv<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">300\u2013500 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">To gange dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Alvorlige\/postoperative; aftagende udbytte derover<\/td>\n<\/tr>\n<\/table>\n<h3 class=\"wp-block-heading\">Oralt<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Niveau<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Dosis<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Hyppighed<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Bem\u00e6rkninger<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Standard oral<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">500 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">En gang dagligt, p\u00e5 tom mave<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Tarmheling \u2014 s\u00e5r, IBS, bet\u00e6ndelse<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">H\u00f8jere oral<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">500\u2013750 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Delt i 2 doser<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Sv\u00e6r GI; 20\u201330 min f\u00f8r m\u00e5ltider<\/td>\n<\/tr>\n<\/table>\n<h3 class=\"wp-block-heading\">V\u00e6gtbaseret<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Kropsv\u00e6gt<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">2,5 mcg\/kg<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">3,3 mcg\/kg<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">5 mcg\/kg<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">60 kg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">150 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">200 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">300 mcg<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">75 kg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">188 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">250 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">375 mcg<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">90 kg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">225 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">300 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">450 mcg<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">110 kg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">275 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">363 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">550 mcg<\/td>\n<\/tr>\n<\/table>\n<h2 class=\"wp-block-heading\">Rekonstituering og dosering (med det medf\u00f8lgende bakteriostatiske vand)<\/h2>\n<p>Hvert Clean Peptides-h\u00e6tteglas leveres med 3 mL bakteriostatisk vand (0,9 % benzylalkohol). Alle tal nedenfor foruds\u00e6tter rekonstituering med de fulde 3 mL. P\u00e5 en standard U-100-insulinspr\u00f8jte er 100 enheder = 1 mL. Hurtig formel: koncentration = h\u00e6tteglasstyrke \u00f7 3 mL, og enheder at tr\u00e6kke op = dosis (mg) \u00d7 300 \u00f7 h\u00e6tteglasstyrke (mg).<\/p>\n<h3 class=\"wp-block-heading\">S\u00e5dan rekonstitueres<\/h3>\n<ol class=\"wp-block-list\">\n<li>Vask h\u00e6nderne og l\u00e6g h\u00e6tteglasset, de 3 mL bakteriostatisk vand, en insulinspr\u00f8jte og spritservietter frem p\u00e5 en ren overflade.<\/li>\n<li>Vip h\u00e6tterne af og aft\u00f8r begge gummipropper med sprit; lad dem luftt\u00f8rre 10\u201315 sekunder.<\/li>\n<li>Tr\u00e6k de fulde 3 mL bakteriostatisk vand op (i tre 1 mL-omgange med en insulinspr\u00f8jte eller i \u00e9n omgang med en 3 mL-spr\u00f8jte).<\/li>\n<li>Tils\u00e6t vandet langsomt, og vinkl n\u00e5len, s\u00e5 det l\u00f8ber ned ad den indvendige glasv\u00e6g \u2014 spr\u00f8jt det aldrig direkte p\u00e5 pulveret.<\/li>\n<li>Opl\u00f8s forsigtigt \u2014 lad h\u00e6tteglasset st\u00e5 1\u20132 minutter, og hvirvl eller rul det derefter mellem h\u00e5ndfladerne, til opl\u00f8sningen er klar. Ryst aldrig.<\/li>\n<li>M\u00e6rk og opbevar i k\u00f8leskab ved 2\u20138 \u00b0C. Resulterende koncentration: 5 mg \u2192 1,67 mg\/mL; 10 mg \u2192 3,33 mg\/mL.<\/li>\n<\/ol>\n<p><strong>Opbevaring:<\/strong> ikke-rekonstitueret pulver i k\u00f8leskab (2\u20138 \u00b0C); rekonstitueret opl\u00f8sning i k\u00f8leskab og anvendt inden for 28\u201330 dage; m\u00e5 ikke fryses; beskyt mod lys og varme.<\/p>\n<h3 class=\"wp-block-heading\">Optr\u00e6ksvolumener med 3 mL \u2014 BPC-157<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">H\u00e6tteglas (Clean Peptides)<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Koncentration<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">250 mcg<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">500 mcg<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">5 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1,67 mg\/mL<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">15 e<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">30 e<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">10 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">3,33 mg\/mL<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">7,5 e<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">15 e<\/td>\n<\/tr>\n<\/table>\n<h2 class=\"wp-block-heading\">Dosering efter m\u00e5l<\/h2>\n<ul class=\"wp-block-list\">\n<li><strong>Sene- og ledb\u00e5ndsskader:<\/strong> 250\u2013500 mcg\/dag SC, en til to gange dagligt, n\u00e6r skaden; 4\u20138 uger (op til 12 ved kroniske tilf\u00e6lde).<\/li>\n<li><strong>Tarmsundhed og GI-heling:<\/strong> 500\u2013750 mcg\/dag helst oralt, p\u00e5 tom mave, 20\u201330 min f\u00f8r m\u00e5ltider; 4\u20138 uger.<\/li>\n<li><strong>Ledsmerter og artrose:<\/strong> 250\u2013300 mcg\/dag SC n\u00e6r leddet; 4\u20138 uger.<\/li>\n<li><strong>Postoperativ restitution:<\/strong> 250\u2013500 mcg to gange dagligt n\u00e6r stedet (efter kirurgens godkendelse); 4\u20138 uger.<\/li>\n<li><strong>Generel restitution og velv\u00e6re:<\/strong> 150\u2013250 mcg\/dag SC i maven; 4\u20136 uger og derefter pause.<\/li>\n<\/ul>\n<p>Konsekvens betyder mere end dosisst\u00f8rrelse \u2014 daglig dosering gennem hele protokollen sl\u00e5r sporadiske h\u00f8jere doser.<\/p>\n<h2 class=\"wp-block-heading\">Injektionsguide<\/h2>\n<ol class=\"wp-block-list\">\n<li>Vask h\u00e6nderne; klarg\u00f8r arbejdsomr\u00e5det.<\/li>\n<li>Aft\u00f8r h\u00e6tteglassets prop; lad den luftt\u00f8rre.<\/li>\n<li>Tr\u00e6k din dosis op; bank bobler ud.<\/li>\n<li>V\u00e6lg sted \u2014 lokalt (n\u00e6r skaden) ved muskuloskeletale problemer; systemisk (nedre mave\/l\u00e5r) ellers.<\/li>\n<li>Rens stedet; lad det luftt\u00f8rre.<\/li>\n<li>Injicer i en l\u00f8ftet hudfold i 45\u00b0.<\/li>\n<li>Bortskaf i en kanyleb\u00f8tte.<\/li>\n<\/ol>\n<blockquote class=\"wp-block-quote\">\n<p>Injicer subkutant n\u00e6r skaden \u2014 ikke ind i senen, ledb\u00e5ndet eller ledkapslen. IM-injektion (25\u201327 G, 90\u00b0) er en mulighed ved dyb muskel. BPC-157 virker b\u00e5de lokalt og systemisk.<\/p>\n<\/blockquote>\n<h2 class=\"wp-block-heading\">Kurvarighed og timing<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Protokol<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Varighed<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Bem\u00e6rkninger<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Standardkur<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">4\u20136 uger<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Akutte\/moderate skader<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Forl\u00e6nget kur<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">8\u201312 uger<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Kronisk tendinopati, postoperativt<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Gentaget kur<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">4\u20136 ugers brug, 2\u20134 ugers pause, gentag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">H\u00e5rdnakkede\/tilbagevendende skader<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Tarmheling<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">4\u20138 uger (oral)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Revurder efter \u00e9n kur<\/td>\n<\/tr>\n<\/table>\n<p>En gang dagligt (ofte om morgenen) eller to gange dagligt med 8\u201312 t mellemrum. Oral dosering p\u00e5 tom mave, 20\u201330 min f\u00f8r et m\u00e5ltid. Ellers ingen strenge timingkrav.<\/p>\n<h2 class=\"wp-block-heading\">Kombinationsprotokoller<\/h2>\n<p>BPC-157 + TB-500 (&#8220;Wolverine Stack&#8221;): lokal reparation + systemisk heling.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Stof<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Dosis<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Hyppighed<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Form\u00e5l<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">BPC-157<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">250 mcg SC<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">En\/to gange dagligt (n\u00e6r skaden)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Lokal reparation, angiogenese<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">TB-500<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">2\u20132,5 mg SC<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">2\u00d7\/uge ved opstart, 1\u00d7\/uge ved vedligeholdelse<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Systemisk antiinflammatorisk<\/td>\n<\/tr>\n<\/table>\n<p>Se den separate <a href=\"https:\/\/cleanpeptides.eu\/da\/tb-500-doseringsguide\/\">TB-500-doseringsguide<\/a> for fulde TB-500-protokoller. BPC-157 + GH-sekretagoger (ipamorelin \/ CJC-1295) tilf\u00f8jer systemisk GH\/IGF-1-st\u00f8tte. GH-sekretagoger injiceres f\u00f8r sengetid, fastende 2 t; BPC-157 n\u00e5r som helst.<\/p>\n<h2 class=\"wp-block-heading\">Sikkerhed, bivirkninger og kontraindikationer<\/h2>\n<p>Enest\u00e5ende sikkerhedsprofil hos dyr \u2014 ingen letal dosis fastlagt hos gnavere. Kliniske humandata er ekstremt begr\u00e6nsede.<\/p>\n<p>Almindelige (milde, forbig\u00e5ende): kvalme (mere ved oral), svimmelhed, r\u00f8dme\/\u00f8mhed ved injektionsstedet, hovedpine, tr\u00e6thed. Sj\u00e6ldne: varme-\/kuldeture, \u00e6ndringer i blodtryk.<\/p>\n<p>Kontraindikationer: aktiv kr\u00e6ft eller tidligere kr\u00e6ft (fremmer angiogenese); graviditet og amning; aktiv infektion p\u00e5 injektionsstedet; forsigtighed ved antikoagulansbehandling.<\/p>\n<p>Interaktioner: NSAID&#8217;er (BPC-157 er gastrobeskyttende hos dyr), blodfortyndere (NO-systemet), dopaminerge l\u00e6gemidler. Regulatorisk: ikke FDA-godkendt; forskningspeptid; forbudt af WADA.<\/p>\n<h2 class=\"wp-block-heading\">Almindelige fejl<\/h2>\n<ul class=\"wp-block-list\">\n<li>At injicere direkte i en sene\/et ledb\u00e5nd (injicer SC n\u00e6r den).<\/li>\n<li>At fortynde h\u00e6tteglasset for meget (\u00f8ger injektionsvolumen\/ubehag).<\/li>\n<li>Ikke at opbevare rekonstituerede h\u00e6tteglas i k\u00f8leskab.<\/li>\n<li>At ryste h\u00e6tteglasset (denaturerer peptidet).<\/li>\n<li>At stoppe for tidligt efter den f\u00f8rste bedring.<\/li>\n<li>At bruge oral dosering til en muskuloskeletal skade (oral er bedst til tarmen).<\/li>\n<li>At genbruge spr\u00f8jter.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Hovedpunkter<\/h2>\n<ul class=\"wp-block-list\">\n<li>15-aminosyrepeptid fra mavesaft; unders\u00f8gt for v\u00e6vsreparation.<\/li>\n<li>Standarddosis 250 mcg SC en til to gange dagligt; 500\u2013750 mcg oralt til tarmheling.<\/li>\n<li>Injicer n\u00e6r skaden for lokal reparation; SC i maven for systemisk effekt.<\/li>\n<li>Rekonstitu\u00e9r med de medf\u00f8lgende 3 mL. Typisk kur 4\u20138 uger.<\/li>\n<li>Bedste kombination: BPC-157 + TB-500.<\/li>\n<li>Opbevar rekonstituerede h\u00e6tteglas i k\u00f8leskab; brug inden for 28\u201330 dage.<\/li>\n<li>Ikke FDA-godkendt; forbudt af WADA.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Referencer<\/h2>\n<ol class=\"wp-block-list\">\n<li>Sikiric P, et al. &#8220;Stable gastric pentadecapeptide BPC 157.&#8221; Curr Pharm Des. 2018;24(18):1990-2001.<\/li>\n<li>Seiwerth S, et al. &#8220;BPC 157&#8217;s effect on healing.&#8221; J Physiol Paris. 1997;91(3-5):173-178.<\/li>\n<li>Chang CH, et al. &#8220;BPC 157 enhances GH receptor expression in tendon fibroblasts.&#8221; Molecules. 2014;19(11):19066-19077.<\/li>\n<li>Staresinic M, et al. &#8220;BPC 157 accelerates healing of transected rat Achilles tendon.&#8221; J Orthop Res. 2003;21(6):976-983.<\/li>\n<li>Sikiric P, et al. &#8220;Brain-gut axis and pentadecapeptide BPC 157.&#8221; Curr Neuropharmacol. 2016;14(8):857-865.<\/li>\n<\/ol>\n<p>\u00a9 2026 Clean Peptides. Undervisningsreference sammensat med uafh\u00e6ngigt materiale fra PeptideWiki. Kun til forskningsform\u00e5l \u2014 ikke til human brug.<\/p>\n<h2 class=\"wp-block-heading\">Download og relaterede ressourcer<\/h2>\n<p><a href=\"https:\/\/cleanpeptides.eu\/wp-content\/uploads\/2026\/07\/02-BPC-157-Dosage-Guide-Clean-Peptides.pdf\" target=\"_blank\" rel=\"noopener\">\ud83d\udcc4 Download PDF-guide<\/a><\/p>\n<p>K\u00f8b BPC-157: <a href=\"https:\/\/cleanpeptides.eu\/product\/bpc-157-5-mg\/\">5 mg<\/a> \u00b7 <a href=\"https:\/\/cleanpeptides.eu\/product\/bpc-157-10-mg\/\">10 mg<\/a><\/p>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div> \n","protected":false},"excerpt":{"rendered":"<p>KUN TIL FORSKNINGSFORM\u00c5L \u2014 IKKE TIL HUMAN BRUG. Clean Peptides giver ikke r\u00e5dgivning om dosering eller anvendelse. Denne side samler [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-10201","page","type-page","status-publish","hentry"],"_hostinger_reach_plugin_has_subscription_block":false,"_hostinger_reach_plugin_is_elementor":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/comments?post=10201"}],"version-history":[{"count":0,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10201\/revisions"}],"wp:attachment":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/media?parent=10201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}